SCHEMBL872934

SCHEMBL872934

Cc1cc(C(=O)Nc2cccc(-c3cncc(C(=O)N=[S@@](C)(=O)c4ccccc4)c3)c2)n(C)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.41
PDGFRB P09619 6/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
KAT6A Q92794 1/20 0.39
MAPK1 P28482 2/20 0.39
PIP4K2A P48426 1/20 0.39
PIP4K2B P78356 1/20 0.39
BRAF P15056 1/20 0.39
FGFR1 P11362 1/20 0.39
LMNA P02545 3/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
HPGD P15428 1/20 0.38
HIF1A Q16665 1/20 0.38
HTT P42858 2/20 0.38
PRKDC P78527 1/20 0.38
ATM Q13315 1/20 0.38
ATR Q13535 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL869770 0.94 KMT2A (0.38) KDRPDGFRBKMT2AMEN1MAPK1
SCHEMBL10183846 0.91 PDGFRB (0.36) KDRPDGFRBKMT2AMEN1MAPK1
SCHEMBL10182506 0.90 KMT2A (0.39) KDRPDGFRBKMT2AMEN1PIP4K2A
SCHEMBL10182347 0.90 KDR (0.37) KDRPDGFRBKMT2AMAPK1PIP4K2A
SCHEMBL10183811 0.88 ROCK2 (0.38) KDRPDGFRBKMT2AMEN1MAPK1
SCHEMBL871885 0.87 HDAC1 (0.36) KDRPDGFRBKMT2AMEN1PIP4K2A
SCHEMBL869452 0.86 KDR (0.44) KDRPDGFRBKMT2AMEN1MAPK1
SCHEMBL869137 0.86 BRAF (0.37) KDRPDGFRBKMT2AMEN1KAT6A
SCHEMBL834782 0.86 KDR (0.59) KDRPDGFRB
SCHEMBL834781 0.86 KDR (0.59) KDRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143410-B2 Kinase inhibitors ALLERGAN, INC. (US) 2012-03-27 US disclosed
US-20090196906-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090196906-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 KDR 51/4885PDGFRB 368/4885KMT2A 1670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.